ADC Therapeutics Down 7% Following New Corporate Presentation
ADC Therapeutics Unveils Strategic Insights in New Presentation
Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlook
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ADC Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 79.78% HC Wainwright & Co. $9 → $8 Maintains Buy 04/15/2024 102.25% HC Wainwright & Co. → $9 Re
Express News | ADC Therapeutics SA : H.c. Wainwright Cuts Target Price to $8 From $9
ADC Therapeutics Ltd's Business At Risk: The Perils of Limited Control in Clinical Trials
Earnings Call Summary | ADC Therapeutics(ADCT.US) Q1 2024 Earnings Conference
The following is a summary of the ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript:Financial Performance:ADC Therapeutics SA reported Q1 2024 revenue of $17.8 million, a 7% sequential incre
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% higher in Monday's premarket activity, as investors hope for the
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday.Shares of BioNTech SE (NASDAQ:BNTX) fell sharply in today's pre-market trading following weaker-than
Express News | ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
ADC Therapeutics | 10-Q: Quarterly report
ADC Therapeutics Reveals Encouraging Phase 2 Trial Outcomes
Express News | ADC Therapeutics Currently Expects Its Cash Runway To Extend Into Q4 Of 2025
Express News | ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
Express News | ADC Therapeutics SA - Company Currently Expects Its Cash Runway to Extend Into Q4 of 2025.
Express News | ADC Therapeutics Q1 Net Income USD -46.606 Million